Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
Tesla Is An AI Company That The Market Won’t Reward For Now
April 24, 2024
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
BLUE Stock News and Mentions of bluebird bio, Inc. Stocktwits
Updated: April 25, 2024 (13:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where bluebird bio Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of bluebird bio, Inc. (BLUE).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the bluebird bio stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of bluebird bio, Inc. (BLUE)
April 25, 2024 (16:43) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for PLUG, EVLV, BLUE, LUNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - bluebird bio ( NASDAQ:BLUE ) , Evolv Technologies ( NASDAQ:EVLV )
BENSALEM, Pa., April 25, 2024 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
April 25, 2024 (16:07) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for EVLV, BLUE, and LUNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - bluebird bio ( NASDAQ:BLUE ) , Evolv Technologies ( NASDAQ:EVLV )
LOS ANGELES, April 25, 2024 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
April 25, 2024 (14:02) / "Zacks Commentary" (by Zacks Equity Research)
Zoetis ( ZTS ) to Report Q1 Earnings: What's in the Cards?
Zoetis' (ZTS) higher companion animal product sales are expected to have driven revenues in the first quarter of 2024 in both the United States and International segments.
In Article Trend: Somewhat-Bullish
April 24, 2024 (16:45) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 24, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ( "bluebird" or the "Company" ) BLUE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) , ...
In Article Trend: Neutral
April 23, 2024 (20:19) / "Benzinga" (by Globe Newswire)
BLUE INVESTOR NOTICE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 23, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of bluebird bio Inc.
In Article Trend: Somewhat-Bullish
April 22, 2024 (01:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm - bluebird bio ( NASDAQ:BLUE ) , Agilon Health ( NYSE:AGL )
NEW YORK, April 21, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Agilon health, inc. AGL, Next Bridge Hydrocarbons, Inc. ( NBH ) , Shoals ...
In Article Trend: Neutral
April 21, 2024 (20:33) / "Benzinga" (by Globe Newswire)
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 21, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. BLUE between April 24, 2023 and December 8, 2023, both dates inclusive ( the "Class Period" ) , of the important May 28, 2024 lead ...
In Article Trend: Somewhat-Bullish
April 20, 2024 (13:00) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE
NEW YORK, April 20, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ( "bluebird" or the "Company" ) ( NASDAQ: BLUE ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) ...
In Article Trend: Neutral
April 19, 2024 (16:35) / "Benzinga" (by Globe Newswire)
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. ( BLUE ) - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, April 19, 2024 ( GLOBE NEWSWIRE ) --
In Article Trend: Neutral
April 19, 2024 (14:00) / "Benzinga" (by Globe Newswire)
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 19, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ( "Blue" or "the Company" ) BLUE and certain of its officers.
In Article Trend: Neutral
April 18, 2024 (21:46) / "Benzinga" (by Globe Newswire)
ROSEN, A TOP RANKED LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 18, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of bluebird bio Inc.
In Article Trend: Somewhat-Bullish
April 18, 2024 (16:07) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for EVLV, BLUE, and LUNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - bluebird bio ( NASDAQ:BLUE ) , Evolv Technologies ( NASDAQ:EVLV )
LOS ANGELES, April 18, 2024 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
April 18, 2024 (01:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm - bluebird bio ( NASDAQ:BLUE ) , Agilon Health ( NYSE:AGL )
NEW YORK, April 17, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Agilon health, inc. AGL, Next Bridge Hydrocarbons, Inc. ( NBH ) , Shoals ...
In Article Trend: Neutral
April 17, 2024 (23:42) / "Benzinga" (by Globe Newswire)
BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline - bluebird bio ( NASDAQ:BLUE )
SAN DIEGO, April 17, 2024 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. BLUE common stock between April 24, 2023 and December 8, 2023.
In Article Trend: Neutral
April 17, 2024 (18:11) / "Benzinga" (by Globe Newswire)
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 17, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. BLUE between April 24, 2023 and December 8, 2023, both dates inclusive ( the "Class Period" ) , of the important May 28, 2024 lead ...
In Article Trend: Somewhat-Bullish
April 17, 2024 (16:48) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for PLUG, EVLV, BLUE, LUNA: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders - bluebird bio ( NASDAQ:BLUE ) , Evolv Technologies ( NASDAQ:EVLV )
BENSALEM, Pa., April 17, 2024 ( GLOBE NEWSWIRE ) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
April 16, 2024 (17:20) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, April 16, 2024 ( GLOBE NEWSWIRE ) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ( "bluebird" or "the Company" ) BLUE for violations of §§10 ( b ) and 20 ( a ) of the Securities Exchange ...
In Article Trend: Neutral
April 15, 2024 (22:09) / "Benzinga" (by Globe Newswire)
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 15, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of bluebird bio Inc.
In Article Trend: Somewhat-Bullish
April 15, 2024 (15:15) / "Benzinga" (by Globe Newswire)
BLUEBIRD BIO, INC. ( NASDAQ: BLUE ) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against bluebird bio, Inc. - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 15, 2024 ( GLOBE NEWSWIRE ) -- Bernstein Liebhard LLP: Do you, or did you, own shares of bluebird bio, Inc. BLUE? Did you purchase your shares between April 24, 2023 and December 8, 2023, inclusive? Did you lose money in your investment in bluebird bio, Inc.?
In Article Trend: Somewhat-Bullish
April 15, 2024 (12:15) / "Motley Fool" (by Alex Carchidi)
Is Bluebird Bio Stock a Buy?
This small biotech is struggling to fly -- and investors should probably steer clear.
In Article Trend: Neutral
April 14, 2024 (01:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Agilon, NBH, Shoals, and Blue and Encourages Investors to Contact the Firm - bluebird bio ( NASDAQ:BLUE ) , Agilon Health ( NYSE:AGL )
NEW YORK, April 13, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Agilon health, inc. AGL, Next Bridge Hydrocarbons, Inc. ( NBH ) , Shoals ...
In Article Trend: Neutral
April 13, 2024 (20:22) / "Motley Fool" (by Prosper Junior Bakiny)
Better Buy: Bluebird Bio Vs. Novavax
Who wins this face-to-face between two beaten-down biotechs?
In Article Trend: Somewhat-Bullish
April 12, 2024 (23:23) / "PR Newswire" (by THE ROSEN LAW FIRM)
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class ... PR ...
In Article Trend: Somewhat-Bullish
April 12, 2024 (16:11) / "Benzinga" (by Globe Newswire)
DEADLINE ALERT for EVLV, BLUE, and LUNA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - bluebird bio ( NASDAQ:BLUE ) , Evolv Technologies ( NASDAQ:EVLV )
LOS ANGELES, April 12, 2024 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
In Article Trend: Neutral
April 12, 2024 (15:00) / "PR Newswire" (by Pomerantz LLP)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE
NEW YORK, April 12, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ( "bluebird" or the "Company" ) ( NASDAQ: BLUE ) . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) ...
In Article Trend: Neutral
April 11, 2024 (22:11) / "Benzinga" (by Globe Newswire)
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 11, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of bluebird bio, Inc. BLUE between April 24, 2023 and December 8, 2023, both dates inclusive ( the "Class Period" ) , of the important May 28, 2024 lead ...
In Article Trend: Somewhat-Bullish
April 11, 2024 (17:22) / "Benzinga" (by Globe Newswire)
Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc. ( BLUE ) of a Class Action Lawsuit and an Upcoming Deadline - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 11, 2024 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ( "bluebird bio" or the "Company" ) BLUE of a class action securities lawsuit.
In Article Trend: Neutral
April 11, 2024 (16:19) / "Benzinga" (by Globe Newswire)
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. ( BLUE ) - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, April 11, 2024 ( GLOBE NEWSWIRE ) --
In Article Trend: Neutral
April 11, 2024 (12:30) / "Motley Fool" (by Prosper Junior Bakiny)
Is This Beaten-Down Stock a Good Acquisition Target?
This company has proven its innovative abilities, but that's not enough to outperform the market.
In Article Trend: Somewhat-Bullish
April 9, 2024 (18:37) / "Benzinga" (by Globe Newswire)
bluebird bio, Inc. ( BLUE ) Class Action Notice: Robbins LLP Reminds Stockholders of Lead Plaintiff Deadline in Class Action Against bluebird bio, Inc. - bluebird bio ( NASDAQ:BLUE )
SAN DIEGO, April 09, 2024 ( GLOBE NEWSWIRE ) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. BLUE common stock between April 24, 2023 and December 8, 2023.
In Article Trend: Neutral
April 9, 2024 (18:20) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, April 09, 2024 ( GLOBE NEWSWIRE ) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ( "bluebird" or "the Company" ) BLUE for violations of §§10 ( b ) and 20 ( a ) of the Securities Exchange ...
In Article Trend: Neutral
April 8, 2024 (18:31) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 08, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ( "bluebird" or the "Company" ) BLUE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or 888.4-POMLAW ) , ...
In Article Trend: Neutral
April 8, 2024 (09:45) / "PR Newswire" (by Levi & Korsinsky)
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUE
NEW YORK, April 8, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ( "bluebird bio" or the "Company" ) ( NASDAQ: BLUE ) of a class action securities lawsuit.
In Article Trend: Neutral
April 6, 2024 (01:00) / "Benzinga" (by Globe Newswire)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Blue, and Luna Innovations and Encourages Investors to Contact the Firm - bluebird bio ( NASDAQ:BLUE ) , Luna Innovations ( NASDAQ:LUNA )
NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bluebird bio Inc. BLUE, and Luna Innovations, Inc.
In Article Trend: Neutral
April 5, 2024 (22:38) / "Benzinga" (by Globe Newswire)
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of bluebird bio Inc.
In Article Trend: Somewhat-Bullish
April 5, 2024 (16:54) / "Benzinga" (by Globe Newswire)
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. ( BLUE ) - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, April 05, 2024 ( GLOBE NEWSWIRE ) -- Glancy Prongay & Murray LLP ( "GPM" ) reminds investors of the upcoming May 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired bluebird bio, Inc. ( "bluebird" or ...
In Article Trend: Neutral
April 5, 2024 (14:00) / "PR Newswire" (by LLC)
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with ... PR ...
In Article Trend: Neutral
April 5, 2024 (14:00) / "Benzinga" (by Globe Newswire)
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 05, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ( "Blue" or "the Company" ) BLUE and certain of its officers.
In Article Trend: Neutral
April 3, 2024 (16:50) / "Benzinga" (by Globe Newswire)
bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 03, 2024 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. BLUE. Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
In Article Trend: Neutral
April 2, 2024 (21:45) / "Benzinga" (by Globe Newswire)
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 02, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of bluebird bio Inc.
In Article Trend: Somewhat-Bullish
April 2, 2024 (20:53) / "Benzinga" (by Globe Newswire)
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of bluebird bio, Inc. ( BLUE ) Investors - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 02, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S.
In Article Trend: Somewhat-Bullish
April 2, 2024 (18:30) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, April 02, 2024 ( GLOBE NEWSWIRE ) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ( "bluebird" or "the Company" ) BLUE for violations of §§10 ( b ) and 20 ( a ) of the Securities Exchange ...
In Article Trend: Neutral
April 1, 2024 (22:00) / "Benzinga" (by Globe Newswire)
ROSEN, NATIONAL TRIAL COUNSEL, Encourages bluebird bio Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 01, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of bluebird bio, Inc. BLUE between April 24, 2023 and December 8, 2023, both dates inclusive ( the ...
In Article Trend: Neutral
April 1, 2024 (16:05) / "Benzinga" (by Globe Newswire)
BLUE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - bluebird bio ( NASDAQ:BLUE )
NEW YORK, April 01, 2024 ( GLOBE NEWSWIRE ) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against bluebird bio, Inc. ( "Blue" or "the Company" ) BLUE and certain of its officers.
In Article Trend: Neutral
April 1, 2024 (09:45) / "PR Newswire" (by Levi & Korsinsky)
Shareholders that lost money on bluebird bio, Inc. ( BLUE ) should contact Levi & Korsinsky about pending Class Action - BLUE
Shareholders that lost money on bluebird bio, Inc. ( BLUE ) should contact Levi & Korsinsky about pending Class Action ... PR ...
In Article Trend: Neutral
April 1, 2024 (05:13) / "Business Insider" (by PRESS RELEASE ACCESSWIRE)
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses to Contact the Firm
FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses to ... - Markets Insider ...
In Article Trend: Neutral
March 31, 2024 (16:05) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, March 31, 2024 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, Inc. ( "bluebird" or the "Company" ) BLUE. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
In Article Trend: Neutral
March 30, 2024 (23:26) / "Business Insider" (by Tipranks)
Is Beam Therapeutics ( NASDAQ:BEAM ) Too Late to the Game?
Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game? - Markets Insider ...
In Article Trend: Somewhat-Bullish
March 30, 2024 (17:08) / "Benzinga" (by Globe Newswire)
BLUE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - bluebird bio ( NASDAQ:BLUE )
SAN DIEGO, March 30, 2024 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the bluebird bio class action lawsuit seeks to represent purchasers or acquirers of bluebird bio, Inc. BLUE common stock between April 24, 2023 and December 8, 2023, both dates ...
In Article Trend: Neutral
March 30, 2024 (05:44) / "Benzinga" (by Globe Newswire)
Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against bluebird bio, Inc. ( BLUE ) - bluebird bio ( NASDAQ:BLUE )
SAN DIEGO, March 30, 2024 ( GLOBE NEWSWIRE ) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired bluebird bio, Inc. BLUE common stock between April 24, 2023 and December 8, 2023.
In Article Trend: Neutral
March 29, 2024 (22:33) / "Benzinga" (by Globe Newswire)
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages bluebird bio Inc. Investors to Inquire About Securities Class Action Investigation - BLUE - bluebird bio ( NASDAQ:BLUE )
NEW YORK, March 29, 2024 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of bluebird bio Inc.
In Article Trend: Somewhat-Bullish
March 29, 2024 (20:18) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm - bluebird bio ( NASDAQ:BLUE )
LOS ANGELES, March 29, 2024 ( GLOBE NEWSWIRE ) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ( "bluebird" or "the Company" ) BLUE for violations of §§10 ( b ) and 20 ( a ) of the Securities Exchange ...
In Article Trend: Neutral
March 29, 2024 (19:10) / "Benzinga" (by Globe Newswire)
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Bluebird Bio Inc. ( BLUE ) - bluebird bio ( NASDAQ:BLUE )
NEW YORK, March 29, 2024 ( GLOBE NEWSWIRE ) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Bluebird Bio ...
In Article Trend: Neutral
March 29, 2024 (10:04) / "Stocknews.com" (by Defense World Staff)
bluebird bio ( NASDAQ:BLUE ) Upgraded to Sell at StockNews.com
StockNews.com upgraded shares of bluebird bio ( NASDAQ:BLUE - Free Report ) to a sell rating in a research report report published on Thursday.
In Article Trend: Somewhat-Bullish
March 29, 2024 (09:20) / "Motley Fool" (by Eric Volkman)
Bluebird Bio Stock Has 138% Upside, According to 1 Wall Street Analyst
Biotech stocks are famously volatile. One analyst feels this one could be volatile enough to produce an outsized gain.
In Article Trend: Neutral
March 29, 2024 (01:00) / "Benzinga" (by Globe Newswire)
BLUE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Bluebird bio Inc. and Encourages Investors to Contact the Firm - bluebird bio ( NASDAQ:BLUE )
NEW YORK, March 28, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Bluebird bio Inc. ( "Blue" or the "Company" ) BLUE in the United States District Court for the District of ...
In Article Trend: Neutral
March 28, 2024 (22:08) / "Benzinga" (by Globe Newswire)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of bluebird bio, Inc. Common Stock and Sets a Lead Plaintiff Deadline of May 28, 2024 - bluebird bio ( NASDAQ:BLUE )
NEW YORK, March 28, 2024 ( GLOBE NEWSWIRE ) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired common stock of bluebird bio, Inc. ( "Blue" or the "Company" ) BLUE between April 24, 2023 and December 8, 2023, ...
In Article Trend: Neutral
March 28, 2024 (21:55) / "Benzinga" (by Globe Newswire)
BLUE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that bluebird bio, Inc. Investors with Substantial Losses Have Opportunity to Lead the bluebird bio Class Action Lawsuit - bluebird bio ( NASDAQ:BLUE )
SAN DIEGO, March 28, 2024 ( GLOBE NEWSWIRE ) -- Robbins Geller Rudman & Dowd LLP announces that the bluebird bio class action lawsuit seeks to represent purchasers or acquirers of bluebird bio, Inc. BLUE common stock between April 24, 2023 and December 8, 2023, inclusive ( the "Class Period" ) .
In Article Trend: Neutral
March 28, 2024 (16:58) / "Investors Business Daily" (by ALLISON GATLIN)
Why Cathie Wood's Darling Crispr Has Tumbled For Five Weeks Straight
Crispr Stock, A Cathie Wood's Holding, Dives For The Fifth Straight Week - Here's Why Investor's Business Daily ...
In Article Trend: Somewhat-Bullish
March 28, 2024 (01:00) / "Benzinga" (by Globe Newswire)
BLUEBIRD ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Bluebird Stockholders and Encourages Investors to Contact the Firm - bluebird bio ( NASDAQ:BLUE )
NEW YORK, March 27, 2024 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bluebird bio Inc. ( "Bluebird" or the "Company" ) BLUE on behalf of Bluebird stockholders.
In Article Trend: Neutral
March 27, 2024 (15:37) / "Zacks Commentary" (by Zacks Equity Research)
bluebird ( BLUE ) Misses on Q4 Revenues, Provides Portfolio Updates
bluebird bio (BLUE) revenues miss the Zacks Consensus Estimate in the fourth quarter. The company progresses with the launch of its three approved gene therapies.
In Article Trend: Somewhat-Bullish
March 27, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Earnings Preview: Bluebird Bio ( BLUE ) Q4 Earnings Expected to Decline
Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
March 22, 2024 (20:00) / "Benzinga" (by Benzinga Insights)
Peering Into bluebird bio's Recent Short Interest - bluebird bio ( NASDAQ:BLUE )
bluebird bio's BLUE short percent of float has risen 4.01% since its last report. The company recently reported that it has 28.59 million shares sold short, which is 15.84% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
March 21, 2024 (16:28) / "CNN"
Opinion: The revolutionary sickle cell therapies
Editor's Note: , Ph.D., is a bioethicist and writer whose work has appeared in The New York Times, Rolling Stone, The Washington Post, The Atlantic and elsewhere. She is also an adjunct professor at Fordham University. The views expressed here are hers. Read more opinion on CNN.
In Article Trend: Neutral
March 19, 2024 (11:44) / "Zacks Commentary" (by Zacks Equity Research)
bluebird ( BLUE ) Gets $175 Million Loan From Hercules, Shares Up
bluebird (BLUE) obtains a $175 million five-year, term loan facility from Hercules that stretches its cash runaway by two years. The company's shares rise on the news.
In Article Trend: Somewhat-Bullish
March 18, 2024 (22:05) / "Motley Fool" (by Eric Volkman)
Why Bluebird Bio Stock Flew Higher Than the Market Today
The company was thrown a financial lifeline.
In Article Trend: Somewhat-Bullish
March 18, 2024 (09:36) / "PR Newswire"
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire
Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... PR ...
In Article Trend: Somewhat-Bullish
March 16, 2024 (12:45) / "Motley Fool" (by Prosper Junior Bakiny)
Is It Too Late to Buy CRISPR Therapeutics Stock?
The biotech has been making a lot of noise since late last year.
In Article Trend: Somewhat-Bullish
March 14, 2024 (13:10) / "Zacks Commentary" (by Zacks Equity Research)
Urogen Pharma ( URGN ) Reports Q4 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of -7.46% and 5.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 13, 2024 (11:50) / "Motley Fool" (by Prosper Junior Bakiny)
March 7, 2024 (14:00) / "Zacks Commentary" (by Zacks Equity Research)
Alimera Sciences ( ALIM ) Reports Q4 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -450% and 4.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 7, 2024 (08:31) / "Motley Fool" (by Alex Carchidi)
1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.
The company now has a chance to get its lead program out the door a bit sooner.
In Article Trend: Somewhat-Bullish
March 5, 2024 (23:56) / "Motley Fool" (by Eric Volkman)
Why Bluebird Bio Stock Dived Into the Red on Tuesday
The biotech has had a tough time of it over the past few years. a pundit's revised take on the company won't improve that situation.
In Article Trend: Somewhat-Bullish
March 4, 2024 (14:10) / "Forbes" (by Joshua Cohen)
Science Continues To Outpace Commercialization Of Cell And Gene Therapies
Biotechnology stocks are experiencing somewhat of a revival this year. It has even lifted some cell and gene therapy company share prices, though certainly not all of them. The continued lack of robust revenue for approved cell and gene therapies is a reminder that being innovative doesn't ...
In Article Trend: Somewhat-Bullish
February 29, 2024 (16:45) / "Benzinga" (by Benzinga Insights)
( BLUE ) - Analyzing bluebird bio's Short Interest - bluebird bio ( NASDAQ:BLUE )
bluebird bio's BLUE short percent of float has risen 4.01% since its last report. The company recently reported that it has 28.59 million shares sold short, which is 15.84% of all regular shares that are available for trading.
In Article Trend: Somewhat-Bullish
February 27, 2024 (19:28) / "Investors Business Daily" (by Investor's Business Daily)
How Beam, Up 28% Today, Is Planning To Take On Crispr
Beam Stock Rockets To Year High As Efforts To Take On Crispr Deepen Investor's Business Daily ...
In Article Trend: Neutral
February 26, 2024 (11:45) / "Motley Fool" (by Alex Carchidi)
Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold
Buy this stock if you're daring, but avoid it for now if you aren't.
In Article Trend: Somewhat-Bullish
Related stocks from Healthcare sector
Becton Dickinson and Company (BDX)
Mesoblast Limited (MESO)
Cue Health Inc. (HLTH)
Cabaletta Bio, Inc. (CABA)
Veeva Systems Inc. (VEEV)
Castle Biosciences, Inc. (CSTL)
Qualigen Therapeutics, Inc. (QLGN)
Allied Healthcare Products, Inc. (AHPI)
UnitedHealth Group, Inc. (UNH)
Clovis Oncology, Inc. (CLVS)
This website uses cookies to ensure you get the best experience on our website